Pioglitazone

Generic Name
Pioglitazone
Brand Names
Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3S
CAS Number
111025-46-8
Unique Ingredient Identifier
X4OV71U42S
Background

Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions
Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
Associated Therapies
-

A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease

First Posted Date
2014-10-15
Last Posted Date
2014-10-16
Lead Sponsor
Command Hospital, India
Target Recruit Count
100
Registration Number
NCT02265276
Locations
🇮🇳

Command Hospital, Panchkula, Haryana, India

The Practical Evidence of Antidiabetic Combination Therapy in Korea

First Posted Date
2014-09-03
Last Posted Date
2019-02-08
Lead Sponsor
Kun-Ho Yoon
Target Recruit Count
216
Registration Number
NCT02231021
Locations
🇰🇷

Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of

Neuroprotection of Pioglitazone in Acute Ischemic Stroke

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2014-07-21
Last Posted Date
2017-01-20
Lead Sponsor
Taipei Medical University Shuang Ho Hospital
Target Recruit Count
4
Registration Number
NCT02195791
Locations
🇨🇳

Taipei Medical Universtiy- Shuang Ho Hospital, New Taipei City, Taiwan

Obesity, Sleep Apnea, and Insulin Resistance

First Posted Date
2014-07-17
Last Posted Date
2017-04-21
Lead Sponsor
Stanford University
Target Recruit Count
45
Registration Number
NCT02192684

Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>

Completed
Conditions
Interventions
First Posted Date
2014-07-04
Last Posted Date
2019-01-16
Lead Sponsor
Takeda
Target Recruit Count
246
Registration Number
NCT02181842

Glycemic Durability After Metformin Failure

First Posted Date
2014-05-20
Last Posted Date
2016-04-20
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
450
Registration Number
NCT02142309
Locations
🇮🇹

Department of Geriatrics and Metabolic Diseases, Naples, Italy

🇮🇹

Katherine Esposito, Naples, Italy

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

First Posted Date
2014-05-08
Last Posted Date
2016-05-13
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
28
Registration Number
NCT02133625
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

First Posted Date
2014-02-26
Last Posted Date
2019-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
192
Registration Number
NCT02072096
Locations
🇺🇸

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States

🇺🇸

Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States

🇺🇸

Carolina Health Specialists, Myrtle Beach, South Carolina, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath